MedPath

Levels of Inflammation in People With Cardiovascular Disease (POSEIDON)

Completed
Conditions
Chronic Kidney Disease
Heart Failure
Cardiovascular Risk
Registration Number
NCT06122961
Lead Sponsor
Novo Nordisk A/S
Brief Summary

This study will collect medical and background information from participants with diseases that affect the heart and blood vessels (cardiovascular disease). Participants will continue their normal care and will not get any treatment other than those the study doctor has prescribed.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
18198
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
High sensitivity C-reactive protein (hsCRP) greater than or equal to 2 mg/L (yes/ no)At visit (day 0)

Count of patient

Secondary Outcome Measures
NameTimeMethod
N-terminal prohormone of brain natriuretic peptide (NT-proBNP)At visit (day 0)

pg/ml

Interleukin 6 (IL-6)At visit (day 0)

pg/ml

Trial Locations

Locations (194)

Mission Cardiovascular Research Institute

🇺🇸

Fremont, California, United States

Texas Institute of Cardiology PA

🇺🇸

McKinney, Texas, United States

Fundacion Favaloro

🇦🇷

Caba, Buenos Aires, Argentina, Argentina

Hospital Italiano Regional Sur

🇦🇷

Bahia Blanca, Buenos Aires, Argentina

Clínica Coronel Suarez

🇦🇷

Coronel Suarez, Buenos Aires, Argentina

Hospital Italiano de la Plata

🇦🇷

La Plata, Buenos Aires, Argentina

Centro Médico CIMEL

🇦🇷

Lanus Este, Buenos Aires, Argentina

INECO Neurociencias Oroño

🇦🇷

Rosario, Santa Fe, Argentina

DIM Clinica Privada

🇦🇷

Buenos Aires, Argentina

Instituto de Investigaciones Clinicas Quilmes SRL

🇦🇷

Buenos Aires, Argentina

Scroll for more (184 remaining)
Mission Cardiovascular Research Institute
🇺🇸Fremont, California, United States

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.